|Bid||0.0700 x 0|
|Ask||0.0710 x 0|
|Day's range||0.0670 - 0.0740|
|52-week range||0.0560 - 0.0840|
|Beta (3Y monthly)||0.07|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
The acquired patches, marketed under the brands CardioCel® and VascuCel®, are processed in a manner that is intended to reduce the risk of calcification. Annualized 2019 sales of these product lines were $7.1 million, mostly in the US and Europe. Guidance on how this acquisition may affect LeMaitre Vascular’s 2019 revenue, operating income and EPS expectations will be provided at the Company’s Q3 2019 earnings call on October 23, 2019.
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! We often see insiders buying up shares in companies thatRead More...